We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
-9.48%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.06B
AUM Growth
-$340M
Cap. Flow
-$46.6M
Cap. Flow %
-2.26%
Top 10 Hldgs %
68.62%
Holding
39
New
2
Increased
10
Reduced
9
Closed
–

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$6.61M
2
PBYI icon
Puma Biotechnology
PBYI
+$5.18M
3
IMMU
Immunomedics Inc
IMMU
+$4.44M
4
FOLD
Amicus Therapeutics
FOLD
+$2.24M
5
ABMD
Abiomed Inc
ABMD
+$2.04M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$26.5M
2
CELG
Celgene Corp
CELG
+$15.1M
3
SAGE
Sage Therapeutics
SAGE
+$10.7M
4
UTHR icon
United Therapeutics
UTHR
+$7.41M
5
ALGN icon
Align Technology
ALGN
+$5.41M

Sector Composition

Rank Sector Weight
1 Healthcare 89.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KLDO
26
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$10.1M 0.49%
866,666
– –
CELG
27
DELISTED
Celgene Corp
CELG
$9.88M 0.48%
106,883
-159,450
-60% -$15.1M
DRNA
28
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.23M 0.25%
331,813
-169,100
-34% -$2.3M
ALIM
29
DELISTED
Alimera Sciences
ALIM
$2.68M 0.13%
200,920
– –
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$1.41M 0.07%
29,500
– –
CYTK icon
31
Cytokinetics
CYTK
$10.5B
$1.39M 0.07%
123,686
– –
VIRX
32
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$845K 0.04%
33,214
– –
MRNS
33
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$520K 0.03%
31,330
+2,775
+10% +$48.2K
ALDX icon
34
Aldeyra Therapeutics
ALDX
$91.7M
$441K 0.02%
+73,500
New +$553K
SPHS
35
DELISTED
Sophiris Bio, Inc.
SPHS
$209K 0.01%
247,000
– –
ACGN
36
DELISTED
Aceragen Inc
ACGN
$206K 0.01%
4,537
– –
NERV icon
37
Minerva Neurosciences
NERV
$187M
$204K 0.01%
+4,540
New +$227K
MLNT
38
DELISTED
Melinta Therapeutics, Inc. Common Stock
MLNT
$67K ﹤0.01%
10,137
– –
OCGN icon
39
Ocugen
OCGN
$475M
$58K ﹤0.01%
5,049
– –
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q2 2019 Portfolio in Review

As of Q2 2019, Palo Alto Investors held 39 positions worth $2.06B, down 14% from $2.4B the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Palo Alto Investors's Q2 2019 filing shows 2 new, 10 increased and 9 reduced positions. Its largest new stake was Aldeyra Therapeutics: 73,500 shares worth $441K. The largest sale was Alexion Pharmaceuticals, an estimated $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Palo Alto Investors's largest Q2 2019 buy was Aldeyra Therapeutics: 73,500 shares worth $441K.
  • Palo Alto Investors added most to Insmed in Q2 2019, an estimated $6.61M increase.
  • Palo Alto Investors's biggest Q2 2019 reduction was Alexion Pharmaceuticals, cutting an estimated $26.5M.
  • Palo Alto Investors's ten largest holdings make up 69% of its $2.06B portfolio in Q2 2019.
  • Palo Alto Investors opened 2 new positions and closed 0 in Q2 2019.
  • Palo Alto Investors's portfolio value fell 14% quarter-over-quarter to $2.06B.

Based on Palo Alto Investors's 13F filing for Q2 2019, filed 14 Aug 2019.